These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 28934253)
21. APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects. Jang Y; Chae JS; Kim OY; Park HJ; Kim JY; Paik JK; Lee SH; Lee JH Atherosclerosis; 2010 Aug; 211(2):512-9. PubMed ID: 20392444 [TBL] [Abstract][Full Text] [Related]
23. Isoflavones and phytosterols contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice. Feng D; Sun JG; Sun RB; Ou-Yang BC; Yao L; Aa JY; Zhou F; Zhang JW; Zhang J; Wang GJ Acta Pharmacol Sin; 2015 Dec; 36(12):1462-72. PubMed ID: 26592515 [TBL] [Abstract][Full Text] [Related]
24. The Anti-hyperlipidemia Effects of Raw Polygonum multiflorum Extract in Vivo. Xian Z; Liu Y; Xu W; Duan F; Guo Z; Xiao H Biol Pharm Bull; 2017; 40(11):1839-1845. PubMed ID: 29093330 [TBL] [Abstract][Full Text] [Related]
25. Effect of DanQi Pill on PPARα, lipid disorders and arachidonic acid pathway in rat model of coronary heart disease. Chang H; Wang Q; Shi T; Huo K; Li C; Zhang Q; Wang G; Wang Y; Tang B; Wang W; Wang Y BMC Complement Altern Med; 2016 Mar; 16():103. PubMed ID: 27000070 [TBL] [Abstract][Full Text] [Related]
26. A genetic variant c.553G > T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug. Bogari NM; Aljohani A; Amin AA; Al-Allaf FA; Dannoun A; Taher MM; Elsayed A; Rednah DI; Elkhatee O; Porqueddu M; Alamanni F; Khogeer SAA; Fawzy A BMC Cardiovasc Disord; 2019 Jan; 19(1):2. PubMed ID: 30606120 [TBL] [Abstract][Full Text] [Related]
27. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Lu Z; Kou W; Du B; Wu Y; Zhao S; Brusco OA; Morgan JM; Capuzzi DM; ; Li S Am J Cardiol; 2008 Jun; 101(12):1689-93. PubMed ID: 18549841 [TBL] [Abstract][Full Text] [Related]
28. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Huang XS; Zhao SP; Bai L; Hu M; Zhao W; Zhang Q Br J Pharmacol; 2009 Oct; 158(3):706-12. PubMed ID: 19694729 [TBL] [Abstract][Full Text] [Related]
29. [Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention]. Jiang FY; Sun LP; Yang J Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Dec; 31(12):1607-10. PubMed ID: 22384544 [TBL] [Abstract][Full Text] [Related]
30. Effects of Xuezhitong in Patients with Hypertriglyceridemia: a Multicentre, Randomized, Double-Blind, Double Simulation, Positive Drug and Placebo Parallel Control Study. Jia W; Li Y; Wan J; Cui X; Lu J; Liu J; Li D; Li L; Zou T; Ding J; Lin Q Cardiovasc Drugs Ther; 2020 Aug; 34(4):525-534. PubMed ID: 32206987 [TBL] [Abstract][Full Text] [Related]
31. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Jakel H; Nowak M; Helleboid-Chapman A; Fruchart-Najib J; Fruchart JC Ann Med; 2006; 38(1):2-10. PubMed ID: 16448983 [TBL] [Abstract][Full Text] [Related]
32. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. Landrier JF; Thomas C; Grober J; Duez H; Percevault F; Souidi M; Linard C; Staels B; Besnard P J Biol Chem; 2004 Oct; 279(44):45512-8. PubMed ID: 15337740 [TBL] [Abstract][Full Text] [Related]
33. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. Huang XS; Zhao SP; Hu M; Bai L; Zhang Q; Zhao W Atherosclerosis; 2010 Jun; 210(2):563-8. PubMed ID: 20047745 [TBL] [Abstract][Full Text] [Related]
34. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Hong XZ; Li LD; Wu LM Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732 [TBL] [Abstract][Full Text] [Related]
35. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Fruchart JC; Duriez P Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610 [TBL] [Abstract][Full Text] [Related]
36. The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V. Bertoccini L; Sentinelli F; Incani M; Bailetti D; Cimini FA; Barchetta I; Cavallo MG; Cossu E; Lenzi A; Loche S; Baroni MG Lipids Health Dis; 2017 Sep; 16(1):179. PubMed ID: 28927406 [TBL] [Abstract][Full Text] [Related]
37. APOA5 gene expression in the human intestinal tissue and its response to in vitro exposure to fatty acid and fibrate. Guardiola M; Alvaro A; Vallvé JC; Rosales R; Solà R; Girona J; Serra N; Duran P; Esteve E; Masana L; Ribalta J Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):756-62. PubMed ID: 21489765 [TBL] [Abstract][Full Text] [Related]
38. Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia. Ding M; Si D; Zhang W; Feng Z; He M; Yang P Exp Ther Med; 2014 Dec; 8(6):1737-1744. PubMed ID: 25371725 [TBL] [Abstract][Full Text] [Related]
39. Red clover extract ameliorates dyslipidemia in streptozotocin-induced diabetic C57BL/6 mice by activating hepatic PPARα. Qiu L; Ye H; Chen L; Hong Y; Zhong F; Zhang T Phytother Res; 2012 Jun; 26(6):860-4. PubMed ID: 22084061 [TBL] [Abstract][Full Text] [Related]
40. Kupffer cells suppress perfluorononanoic acid-induced hepatic peroxisome proliferator-activated receptor α expression by releasing cytokines. Fang X; Zou S; Zhao Y; Cui R; Zhang W; Hu J; Dai J Arch Toxicol; 2012 Oct; 86(10):1515-25. PubMed ID: 22648072 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]